Literature DB >> 201374

Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.

M G Hanna, L C Peters.   

Abstract

We evaluated the use of Bacillus Calmette-Guérin admixed with tumor cells as a vaccine to induce systemic tumor immunity for therapy of subclinical (micrometastatic) disease. In several experiments inbred strain 2 guinea pigs were given i.v. injections of either 10(4), 10(5), or 10(6) syngeneic L10 hepatocarcinoma cells, and initial vaccinations were administered either 1 or 4 days after tumor inocluation. Variables in vaccine preparation, such as ratio of viable Bacillus Calmette-Guérin organisms to tumor cells, procedures for freezing the tumor cells, X-ray treatment of tumor cells, and vaccination regimen were evaluated. The studies demonstrated that under defined conditions nontumorigenic vaccines of Bacillus Calmette-Guérin and tumor cells can cure the majority of animals of otherwise lethal visceral micrometastases.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 201374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine.

Authors:  B S Sharma; L Balazs; A Jin; J C Wang; W B Jolley; R K Robins
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Eradication of microscopic hepatic metastases by active specific immunization.

Authors:  S Sukumar; J T Hunter; N Terata; H J Rapp
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

4.  Antimetastatic effect of Lactobacillus casei YIT9018 (LC 9018) on a highly metastatic variant of B16 melanoma in C57BL/6J mice.

Authors:  T Matsuzaki; T Yokokura; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.

Authors:  W M Mulder; H Koenen; A J van de Muysenberg; E Bloemena; J Wagstaff; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

6.  Menningococcal antigens (MA): a novel immune stimulant in experimental neoplasia.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; J M Dupuy; V V Micusan; R E Falk
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.

Authors:  E F Wheelock; M K Robinson; G A Truitt
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

8.  Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice.

Authors:  T Kataoka; F Oh-hashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Anti-tumour activity of Lactobacillus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs.

Authors:  T Matsuzaki; T Yokokura; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 10.  Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment.

Authors:  Bailee H Sliker; Paul M Campbell
Journal:  Vaccines (Basel)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.